Citations (86)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Tiago M. Bonde, Hans Garmo, Pär Stattin, Per Nilsson, Adalsteinn Gunnlaugsson, Daniela Swanberg & David Robinson. (2023) Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists. Acta Oncologica 62:12, pages 1815-1821.
Read now
Read now
Renata Zelic, Francesca Giunchi, Jonna Fridfeldt, Jessica Carlsson, Sabina Davidsson, Luca Lianas, Cecilia Mascia, Daniela Zugna, Luca Molinaro, Per Henrik Vincent, Gianluigi Zanetti, Ove Andrén, Lorenzo Richiardi, Olof Akre, Michelangelo Fiorentino & Andreas Pettersson. (2022) Prognostic Utility of the Gleason Grading System Revisions and Histopathological Factors Beyond Gleason Grade. Clinical Epidemiology 14, pages 59-70.
Read now
Read now
Kaire Innos, Keiu Paapsi, Indrek Alas, Peep Baum, Martin Kivi, Mihhail Kovtun, Rauno Okas, Helis Pokker, Olga Rajevskaja, Aleksandra Rautio, Mikk Saretok, Elari Valk, Mihhail Žarkovski, Gleb Denissov & Katrin Lang. (2022) Evidence of overestimating prostate cancer mortality in Estonia: a population-based study. Scandinavian Journal of Urology 56:5-6, pages 359-364.
Read now
Read now
Tiago M. Bonde, Marcus Westerberg, Markus Aly, Martin Eklund, Jan Adolfsson, Anna Bill-Axelson, Hans Garmo, Pär Stattin & David Robinson. (2022) Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists. Scandinavian Journal of Urology 56:3, pages 169-175.
Read now
Read now
Olof Gunnarsson, Sonny Schelin, Lars Brudin, Stefan Carlsson & Jan-Erik Damber. (2019) Triple treatment of high-risk prostate cancer. A matched cohort study with up to 19 years follow-up comparing survival outcomes after triple treatment and treatment with hormones and radiotherapy. Scandinavian Journal of Urology 53:2-3, pages 102-108.
Read now
Read now
Sven Löffeler, Adrian Halland, Harald Weedon-Fekjær, Anastasia Nikitenko, Christian Lycke Ellingsen & Erik Skaaheim Haug. (2018) High Norwegian prostate cancer mortality: evidence of over-reporting. Scandinavian Journal of Urology 52:2, pages 122-128.
Read now
Read now
Joachim Aidt Becker, Kasper Drimer Berg, Martin Andreas Røder, Klaus Brasso & Peter Iversen. (2018) Cytoreductive prostatectomy in metastatic prostate cancer: a systematic review. Scandinavian Journal of Urology 52:1, pages 1-7.
Read now
Read now
Kaire Innos, Aleksei Baburin, Andres Kotsar, Ivar-Endrik Eiche & Katrin Lang. (2017) Prostate cancer incidence, mortality and survival trends in Estonia, 1995–2014. Scandinavian Journal of Urology 51:6, pages 442-449.
Read now
Read now
Katarina Tomic, Marcus Westerberg, David Robinson, Hans Garmo & Pär Stattin. (2016) Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden. Acta Oncologica 55:12, pages 1461-1466.
Read now
Read now
Michael Jan, Stephanie E. Bonn, Arvid Sjölander, Fredrik Wiklund, Pär Stattin, Erik Holmberg, Henrik Grönberg & Katarina Bälter. (2016) The roles of stress and social support in prostate cancer mortality. Scandinavian Journal of Urology 50:1, pages 47-55.
Read now
Read now
Katarina Tomic, Anders Berglund, David Robinson, Marie Hjälm-Eriksson, Stefan Carlsson, Mats Lambe & Pär Stattin. (2015) Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncologica 54:2, pages 158-163.
Read now
Read now
Håkon Wæhre, Ljiljana Vlatkovic, Milada Cvancarova, Elisabeth Paus, Sophie D. Fosså & Håvard E. Danielsen. (2014) Fifteen-year mortality after radical prostatectomy: Which factors are available for patient counselling?. Scandinavian Journal of Urology 48:2, pages 123-130.
Read now
Read now
Ingela Franck Lissbrant, Hans Garmo, Anders Widmark & Pär Stattin. (2013) Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncologica 52:8, pages 1593-1601.
Read now
Read now
Rebecka Godtman, Erik Holmberg, Johan Stranne & Jonas Hugosson. (2011) High accuracy of Swedish death certificates in men participating in screening for prostate cancer: A comparative study of official death certificates with a cause of death committee using a standardized algorithm. Scandinavian Journal of Urology and Nephrology 45:4, pages 226-232.
Read now
Read now
Eva Hagel, Hans Garmo, Anna Bill-Axelson, Ola Bratt, Jan-Erik Johansson, Jan Adolfsson, Mats Lambe & Pär Stattin. (2009) PCBaSe Sweden: A register-based resource for prostate cancer research. Scandinavian Journal of Urology and Nephrology 43:5, pages 342-349.
Read now
Read now
Articles from other publishers (71)
H.V. Stroomberg, A. Røder, J.T. Helgstrand, K. Brasso & S.B. Larsen. (2023) Evaluation of causes of death among Danish men with initial non-malignant histopathology of the prostate. Ethics, Medicine and Public Health 30, pages 100930.
Crossref
Crossref
Aurélien Belot, Vincent Camus, Cédric Portugues, Jérome Paget, Loic Chartier, Pascale Cony‐Makhoul, Hervé Tilly & Clémentine Joubert. (2023)
Long‐term excess mortality and net survival among elderly diffuse large B‐cell lymphoma patients after front‐line
R‐CHOP
treatment
. British Journal of Haematology 201:5, pages 857-864.
Crossref
Crossref
Sylvia H. J. Jochems, Josef Fritz, Christel Häggström, Pär Stattin & Tanja Stocks. (2023) Prediagnostic markers of insulin resistance and prostate cancer risk and death: A pooled study. Cancer Medicine 12:12, pages 13732-13744.
Crossref
Crossref
Andri Wilberg Orrason, Johan Styrke, Hans Garmo & Pär Stattin. (2022) Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden. BJU International 131:4, pages 486-493.
Crossref
Crossref
Pär Stattin, Marcus Westerberg, Ingela Franck Lissbrant, Marie Hjälm Eriksson, Anders Kjellman, Anders Ullén, Zdravko Vassilev, Per Sandstrom, Rachel Weinrib, David Martinez & Xabier Garcia-Albeniz. (2023) Real World Outcomes in Patients With Metastatic, Castration-Resistant Prostate Cancer Treated With Radium-223 in Routine Clinical Practice in Sweden. Clinical Genitourinary Cancer 21:1, pages 107.e1-107.e9.
Crossref
Crossref
Qingzhao Zhang, Hao Chai, Weijuan Liang & Shuangge Ma. 2023. Proceedings of the Second International Forum on Financial Mathematics and Financial Technology. Proceedings of the Second International Forum on Financial Mathematics and Financial Technology
37
63
.
Lars Björnebo, Tobias Nordström, Andrea Discacciati, Thorgerdur Palsdottir, Markus Aly, Henrik Grönberg, Martin Eklund & Anna Lantz. (2022) Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality. JAMA Oncology 8:7, pages 1019.
Crossref
Crossref
Per‐Olof Lundgren, Bernhard Tribukait, Anders Kjellman, Ulf Norming, Kiran Jagarlmudi & Ove Gustafsson. (2022) Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer. The Prostate 82:8, pages 911-916.
Crossref
Crossref
Johan Björklund, Pär Stattin, Erik Rönmark, Markus Aly & Olof Akre. (2021) The 90‐day cause‐specific mortality after radical prostatectomy: a nationwide population‐based study. BJU International 129:3, pages 318-324.
Crossref
Crossref
Christian Carrwik, Claes Olerud & Yohan Robinson. (2021) Survival after surgery for spinal metastatic disease: a nationwide multiregistry cohort study. BMJ Open 11:11, pages e049198.
Crossref
Crossref
Per‐Olof Lundgren, Anders Kjellman, Ulf Norming & Ove Gustafsson. (2021) Association between one‐time prostate‐specific antigen (PSA) test with free/total PSA ratio and prostate cancer mortality: A 30‐year prospective cohort study. BJU International 128:4, pages 490-496.
Crossref
Crossref
Andri Wilberg Orrason, Hans Garmo, Johan Styrke, Paul W Dickman & Pär Stattin. (2021) Comparison of Relative Survival and Cause-Specific Survival in Men With Prostate Cancer According to Age and Risk Category: A Nationwide, Population-Based Study. American Journal of Epidemiology 190:10, pages 2053-2063.
Crossref
Crossref
Richard Shore, Jingru Yu, Weimin Ye, Jesper Lagergren, Martin Rutegård, Olof Akre, Pär Stattin & Mats Lindblad. (2021) Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer. Scientific Reports 11:1.
Crossref
Crossref
S. Eloranta, K. E. Smedby, P. W. Dickman & T. M. Andersson. (2020) Cancer survival statistics for patients and healthcare professionals – a tutorial of real‐world data analysis. Journal of Internal Medicine 289:1, pages 12-28.
Crossref
Crossref
Giuseppe Fallara, Ingela Franck Lissbrant, Johan Styrke, Francesco Montorsi, Hans Garmo & Pär Stattin. (2020) Observational study on time on treatment with abiraterone and enzalutamide. PLOS ONE 15:12, pages e0244462.
Crossref
Crossref
David Thurtle, Ola Bratt, Pär Stattin, Paul Pharoah & Vincent Gnanapragasam. (2020) Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe). BMC Medicine 18:1.
Crossref
Crossref
Cameron M. Wright, Anna K. Nowak, Georgia Halkett & Rachael E. Moorin. (2020) Incorporating competing risk theory into evaluations of changes in cancer survival: making the most of cause of death and routinely linked sociodemographic data. BMC Public Health 20:1.
Crossref
Crossref
Kirsti Aas, Sophie Dorothea Fosså, Tor Åge Myklebust, Bjørn Møller, Rune Kvåle, Ljiljana Vlatkovic & Viktor Berge. (2020) Increased curative treatment is associated with decreased prostate cancer‐specific and overall mortality in senior adults with high‐risk prostate cancer; results from a national registry‐based cohort study. Cancer Medicine 9:18, pages 6646-6657.
Crossref
Crossref
Andreas Pettersson, Daniel Alm, Hans Garmo, Marie Hjelm Eriksson, Enrique Castellanos, Lennart Åström, Jon Kindblom, Anders Widmark, Adalsteinn Gunnlaugsson, Ingela Franck Lissbrant, Per Nilsson & Pär Stattin. (2020) Comparative Effectiveness of Different Radical Radiotherapy Treatment Regimens for Prostate Cancer: A Population-Based Cohort Study. JNCI Cancer Spectrum 4:2.
Crossref
Crossref
Renata Zelic, Hans Garmo, Daniela Zugna, Pär Stattin, Lorenzo Richiardi, Olof Akre & Andreas Pettersson. (2020) Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study. European Urology 77:2, pages 180-188.
Crossref
Crossref
Renata Zelic, Daniela Zugna, Matteo Bottai, Ove Andrén, Jonna Fridfeldt, Jessica Carlsson, Sabina Davidsson, Valentina Fiano, Michelangelo Fiorentino, Francesca Giunchi, Chiara Grasso, Luca Lianas, Cecilia Mascia, Luca Molinaro, Gianluigi Zanetti, Lorenzo Richiardi, Andreas Pettersson & Olof Akre. (2019) Estimation of Relative and Absolute Risks in a Competing-Risks Setting Using a Nested Case-Control Study Design: Example From the ProMort Study. American Journal of Epidemiology 188:6, pages 1165-1173.
Crossref
Crossref
Mary Nguyen-Nielsen, Henrik Møller, Anne Tjønneland & Michael Borre. (2019) Causes of death in men with prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata). Cancer Epidemiology 59, pages 249-257.
Crossref
Crossref
Jie Ren, Yinhao Du, Shaoyu Li, Shuangge Ma, Yu Jiang & Cen Wu. (2019) Robust network‐based regularization and variable selection for high‐dimensional genomic data in cancer prognosis. Genetic Epidemiology 43:3, pages 276-291.
Crossref
Crossref
Walter Cazzaniga, Eugenio Ventimiglia, Massimo Alfano, David Robinson, Ingela Franck Lissbrant, Stefan Carlsson, Johan Styrke, Francesco Montorsi, Andrea Salonia & Pär Stattin. (2019) Mini Review on the Use of Clinical Cancer Registers for Prostate Cancer: The National Prostate Cancer Register (NPCR) of Sweden. Frontiers in Medicine 6.
Crossref
Crossref
Lara Rodriguez-Sanchez, Pablo Fernández-Navarro, Gonzalo López-Abente, Olivier Nuñez, Nerea Fernández de Larrea-Baz, Jose Juan Jimenez-Moleón, Álvaro Páez Borda, Marina Pollán & Beatriz Perez-Gomez. (2019) Different spatial pattern of municipal prostate cancer mortality in younger men in Spain. PLOS ONE 14:1, pages e0210980.
Crossref
Crossref
V. J. Gnanapragasam, O. Bratt, K. Muir, L. S. Lee, H. H. Huang, P. Stattin & A. Lophatananon. (2018) The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. BMC Medicine 16:1.
Crossref
Crossref
Weiqiang Li, Mridu Middha, Mesude Bicak, Daniel D. Sjoberg, Emily Vertosick, Anders Dahlin, Christel Häggström, Göran Hallmans, Ann-Charlotte Rönn, Pär Stattin, Olle Melander, David Ulmert, Hans Lilja & Robert J. Klein. (2018) Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival. European Urology 74:6, pages 710-719.
Crossref
Crossref
Daniel D. Sjoberg, Andrew J. Vickers, Melissa Assel, Anders Dahlin, Bing Ying Poon, David Ulmert & Hans Lilja. (2018) Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men. European Urology 73:6, pages 941-948.
Crossref
Crossref
David Robinson, Hans Garmo, Ingela Franck Lissbrant, Anders Widmark, Andreas Pettersson, Adalsteinn Gunnlaugsson, Jan Adolfsson, Ola Bratt, Per Nilsson & Pär Stattin. (2018) Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study. European Urology 73:4, pages 502-511.
Crossref
Crossref
Cen Wu, Yu Jiang, Jie Ren, Yuehua Cui & Shuangge Ma. (2018) Dissecting gene-environment interactions: A penalized robust approach accounting for hierarchical structures. Statistics in Medicine 37:3, pages 437-456.
Crossref
Crossref
A. Pettersson, D. Robinson, H. Garmo, L. Holmberg & P. Stattin. (2018) Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Annals of Oncology 29:2, pages 377-385.
Crossref
Crossref
Frederik Birkebæk Thomsen, Fredrik Sandin, Hans Garmo, Ingela Franck Lissbrant, Göran Ahlgren, Mieke Van Hemelrijck, Jan Adolfsson, David Robinson & Pär Stattin. (2017) Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study. European Urology 72:6, pages 920-928.
Crossref
Crossref
R. Kvåle, T.Å. Myklebust, G. Engholm, S. Heinävaara, E. Wist & B. Møller. (2017) Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975–2013. International Journal of Cancer 141:11, pages 2228-2242.
Crossref
Crossref
Hao Chai, Xingjie Shi, Qingzhao Zhang, Qing Zhao, Yuan Huang & Shuangge Ma. (2017) Analysis of cancer gene expression data with an assisted robust marker identification approach. Genetic Epidemiology 41:8, pages 779-789.
Crossref
Crossref
Prabhakar RajanPrasanna SooriakumaranTommy NybergOlof AkreStefan CarlssonLars EgevadGunnar SteineckN. Peter Wiklund. (2017) Effect of Comorbidity on Prostate Cancer–Specific Mortality: A Prospective Observational Study. Journal of Clinical Oncology 35:31, pages 3566-3574.
Crossref
Crossref
Hao Chai, Qingzhao Zhang, Yu Jiang, Guohua Wang, Sanguo Zhang, Syed Ejaz Ahmed & Shuangge Ma. (2017) Identifying gene-environment interactions for prognosis using a robust approach. Econometrics and Statistics 4, pages 105-120.
Crossref
Crossref
Prasanna Sooriakumaran, Tommy Nyberg, Olof Akre, Anders Widmark, Freddie Hamdy, Markus Graefen, Stefan Carlsson, Gunnar Steineck & N. Peter Wiklund. (2017) Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy. European Urology 72:3, pages 345-351.
Crossref
Crossref
Hannah Louise Brooke, Mats Talbäck, Jesper Hörnblad, Lars Age Johansson, Jonas Filip Ludvigsson, Henrik Druid, Maria Feychting & Rickard Ljung. (2017) The Swedish cause of death register. European Journal of Epidemiology 32:9, pages 765-773.
Crossref
Crossref
Pär Stattin, Fredrik Sandin, Frederik Birkebæk Thomsen, Hans Garmo, David Robinson, Ingela Franck Lissbrant, Håkan Jonsson & Ola Bratt. (2017) Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. European Urology 72:1, pages 125-134.
Crossref
Crossref
Therese M.-L. Andersson, Mark J. Rutherford & Keith Humphreys. (2017) Assessment of lead-time bias in estimates of relative survival for breast cancer. Cancer Epidemiology 46, pages 50-56.
Crossref
Crossref
Stephen D Walter, Harry J de Koning, Jonas Hugosson, Kirsi Talala, Monique J Roobol, Sigrid Carlsson, Marco Zappa, Vera Nelen, Maciej Kwiatkowski, Álvaro Páez, Sue Moss & Anssi Auvinen. (2016) Impact of cause of death adjudication on the results of the European prostate cancer screening trial. British Journal of Cancer 116:1, pages 141-148.
Crossref
Crossref
Kathryn M. Wilson, Sarah C. Markt, Fang Fang, Caroline Nordenvall, Jennifer R. Rider, Weimin Ye, Hans-Olov Adami, Pär Stattin, Olof Nyrén & Lorelei A. Mucci. (2016) Snus use, smoking and survival among prostate cancer patients. International Journal of Cancer 139:12, pages 2753-2759.
Crossref
Crossref
Rami Klaff, Johan Rosell, Eberhard Varenhorst & Gabriel Sandblom. (2016) The Long-term Disease-specific Mortality of Low-risk Localized Prostate Cancer: A Prospective Population-based Register Study Over Two Decades. Urology 91, pages 77-82.
Crossref
Crossref
Mieke Van Hemelrijck, Yasin Folkvaljon, Jan Adolfsson, Olof Akre, Lars Holmberg, Hans Garmo & Pär Stattin. (2016) Causes of death in men with localized prostate cancer: a nationwide, population-based study. BJU International 117:3, pages 507-514.
Crossref
Crossref
Dominic C Marshall, Thomas E Webb, Richard A Hall, Justin D Salciccioli, Raghib Ali & Mahiben Maruthappu. (2016) Trends in UK regional cancer mortality 1991–2007. British Journal of Cancer 114:3, pages 340-347.
Crossref
Crossref
Jinkyung HaAlexander Tsodikov. (2015) Semiparametric estimation in the proportional hazard model accounting for a misclassified cause of failure. Biometrics 71:4, pages 941-949.
Crossref
Crossref
Ola Bratt, Yasin Folkvaljon, Marie Hjälm Eriksson, Olof Akre, Stefan Carlsson, Linda Drevin, Ingela Franck Lissbrant, Danil Makarov, Stacy Loeb & Pär Stattin. (2015) Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer. European Urology 68:1, pages 53-58.
Crossref
Crossref
M. Torniainen, E. Mittendorfer-Rutz, A. Tanskanen, C. Bjorkenstam, J. Suvisaari, K. Alexanderson & J. Tiihonen. (2014) Antipsychotic Treatment and Mortality in Schizophrenia. Schizophrenia Bulletin 41:3, pages 656-663.
Crossref
Crossref
Katarina Tomic, Fredrik Sandin, Annette Wigertz, David Robinson, Mats Lambe & Pär Stattin. (2015) Evaluation of data quality in the National Prostate Cancer Register of Sweden. European Journal of Cancer 51:1, pages 101-111.
Crossref
Crossref
Michael J. CrowtherPaul C. Lambert. (2014) A general framework for parametric survival analysis. Statistics in Medicine 33:30, pages 5280-5297.
Crossref
Crossref
Karl-Johan Lundström, Linda Drevin, Stefan Carlsson, Hans Garmo, Stacy Loeb, Pär Stattin & Anna Bill-Axelson. (2014) Nationwide Population Based Study of Infections after Transrectal Ultrasound Guided Prostate Biopsy. Journal of Urology 192:4, pages 1116-1122.
Crossref
Crossref
Cristin D. Runfola, Laura M. Thornton, Emily M. Pisetsky, Cynthia M. Bulik & Andreas Birgegård. (2014) Self-image and suicide in a Swedish national eating disorders clinical register. Comprehensive Psychiatry 55:3, pages 439-449.
Crossref
Crossref
P. Stattin, S. Carlsson, B. Holmstrom, A. Vickers, J. Hugosson, H. Lilja & H. Jonsson. (2014) Prostate Cancer Mortality in Areas With High and Low Prostate Cancer Incidence. JNCI Journal of the National Cancer Institute 106:3, pages dju007-dju007.
Crossref
Crossref
M. Van Hemelrijck, A. Wigertz, F. Sandin, H. Garmo, K. Hellstrom, P. Fransson, A. Widmark, M. Lambe, J. Adolfsson, E. Varenhorst, J.-E. Johansson, P. Stattin, L. Drevin, A. Bill-Axelson, D. Robinson & O. Akre. (2012) Cohort Profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. International Journal of Epidemiology 42:4, pages 956-967.
Crossref
Crossref
Sam Ladjevardi, Anders Berglund, Eberhard Varenhorst, Ola Bratt, Anders Widmark & Gabriel Sandblom. (2012)
Treatment with curative intent and survival in men with high‐risk prostate cancer. A population‐based study of 11 380 men with serum
PSA
level 20–100 ng/
mL
. BJU International 111:3, pages 381-388.
Crossref
Crossref
Jennifer R. Rider, Fredrik Sandin, Ove Andrén, Peter Wiklund, Jonas Hugosson & Pär Stattin. (2013) Long-term Outcomes Among Noncuratively Treated Men According to Prostate Cancer Risk Category in a Nationwide, Population-based Study. European Urology 63:1, pages 88-96.
Crossref
Crossref
Ruth Etzioni, Lorelei Mucci, Shu Chen, Jan-Erik Johansson, Katja Fall & Hans-Olov Adami. (2012) Increasing Use of Radical Prostatectomy for Nonlethal Prostate Cancer in Sweden. Clinical Cancer Research 18:24, pages 6742-6747.
Crossref
Crossref
M. M. Epstein, G. Edgren, J. R. Rider, L. A. Mucci & H.-O. Adami. (2012) Temporal Trends in Cause of Death Among Swedish and US Men with Prostate Cancer. JNCI Journal of the National Cancer Institute 104:17, pages 1335-1342.
Crossref
Crossref
Olof Akre, Hans Garmo, Jan Adolfsson, Mats Lambe, Ola Bratt & Pär Stattin. (2011) Mortality Among Men with Locally Advanced Prostate Cancer Managed with Noncurative Intent: A Nationwide Study in PCBaSe Sweden. European Urology 60:3, pages 554-563.
Crossref
Crossref
Mara M Epstein, Julie L Kasperzyk, Ove Andrén, Edward L Giovannucci, Alicja Wolk, Niclas Håkansson, Swen-Olof Andersson, Jan-Erik Johansson, Katja Fall & Lorelei A Mucci. (2011) Dietary zinc and prostate cancer survival in a Swedish cohort. The American Journal of Clinical Nutrition 93:3, pages 586-593.
Crossref
Crossref
Anders Berglund, Hans Garmo, Carol Tishelman, Lars Holmberg, Pär Stattin & Mats Lambe. (2011) Comorbidity, Treatment and Mortality: A Population Based Cohort Study of Prostate Cancer in PCBaSe Sweden. Journal of Urology 185:3, pages 833-840.
Crossref
Crossref
Matias RiihimäkiHauke ThomsenAndreas BrandtJan Sundquist & Kari Hemminki. (2011) What Do Prostate Cancer Patients Die Of?. The Oncologist 16:2, pages 175-181.
Crossref
Crossref
S.J. Otto, P.J. van Leeuwen, J.W. Hoekstra, J.W. Merckelbach, J.H.M. Blom, F.H. Schröder, M.J. Roobol & H.J. de Koning. (2010) Blinded and uniform causes of death verification in cancer screening: A major influence on the outcome of a prostate cancer screening trial?. European Journal of Cancer 46:17, pages 3061-3067.
Crossref
Crossref
Benny Holmström, Erik Holmberg, Lars Egevad, Jan Adolfsson, Jan-Erik Johansson, Jonas Hugosson & Pär Stattin. (2010) Outcome of Primary Versus Deferred Radical Prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. Journal of Urology 184:4, pages 1322-1327.
Crossref
Crossref
Tanja Stocks, Maria‐Pia Hergens, Anders Englund, Weimin Ye & Pär Stattin. (2010) Blood pressure, body size and prostate cancer risk in the Swedish Construction Workers cohort. International Journal of Cancer 127:7, pages 1660-1668.
Crossref
Crossref
R. Kvåle, B. Møller, A. Angelsen, O. Dahl, S.D. Fosså, O.J. Halvorsen, L. Hoem, A. Solberg, R. Wahlqvist & F. Bray. (2010) Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980–2007. Cancer Epidemiology 34:4, pages 359-367.
Crossref
Crossref
P. Stattin, E. Holmberg, J.-E. Johansson, L. Holmberg, J. Adolfsson & J. Hugosson. (2010) Outcomes in Localized Prostate Cancer: National Prostate Cancer Register of Sweden Follow-up Study. JNCI Journal of the National Cancer Institute 102:13, pages 950-958.
Crossref
Crossref
David A. Brown, Fredrik Lindmark, Pär Stattin, Katarina Bälter, Hans-Olov Adami, Sigun L. Zheng, Jianfeng Xu, William B. Isaacs, Henrik Grönberg, Samuel N. Breit & Fredrik E. Wiklund. (2009) Macrophage Inhibitory Cytokine 1: A New Prognostic Marker in Prostate Cancer. Clinical Cancer Research 15:21, pages 6658-6664.
Crossref
Crossref
Jennifer R. Stark, Fredrik Wiklund, Henrik Grönberg, Fredrick Schumacher, Jennifer A. Sinnott, Meir J. Stampfer, Lorelei A. Mucci & Peter Kraft. (2009) Toll-like Receptor Signaling Pathway Variants and Prostate Cancer Mortality. Cancer Epidemiology, Biomarkers & Prevention 18:6, pages 1859-1863.
Crossref
Crossref
O Andrèn, H Garmo, L Mucci, S-O Andersson, J-E Johansson & K Fall. (2008) Incidence and mortality of incidental prostate cancer: a Swedish register-based study. British Journal of Cancer 100:1, pages 170-173.
Crossref
Crossref
G. Tuccitto, P. Checchin & G. Anselmo. (2018) Rehabilitation in Genuine Stress Incontinence: Past and Present Experiences. Urologia Journal 60:2, pages 200-202.
Crossref
Crossref